Skip to content
Home
Company
About Us
Leadership
Management
Board of Directors
Scientific
Advisory Board
Science
Evorpacept
Publications
Pipeline
Clinical Trials
Expanded
Access Policy
Careers
Current Jobs
Investors
Overview
News & Events
Stock Information
Corporate Governance
Financials & Filings
IR Resources
Contact
Discovery of Monoclonal Antibodies Targeting Myeloid Checkpoint SIRPα to Enhance Anti-Tumor Immunity
Post navigation
Previous:
ALX148 Blocks CD47 and Enhances Innate and Adaptive Antitumor Immunity with a Favorable Safety Profile
Next:
Antibodies to SIRPα Enhance Innate and Adaptive Immune Responses to Promote Anti-Tumor Activity
